Pharmaceutical Technology's In the Lab eNewsletter
Solentim and ATUM have announced a technology collaboration agreement that will focus on the creation of an efficient cell line development solution for biotherapeutic drug developers.
Solentim, specialist in cell-line development instrumentation, and ATUM, a bioengineering company, have announced a technology collaboration agreement that will focus on the creation of an efficient cell line development solution for biotherapeutic drug developers.
Creation of the cell-line development solution will be achieved through the integration of Solentim’s verified in-situ plate seeding (VIPS) hardware along with ATUM’s expression technology, Leap-In Transposase, it was revealed in a Jan. 14, 2019 press release.
“This collaboration allows Solentim and ATUM to offer a unique integrated solution to our customers and significantly accelerate stable cell line development workflows,” said Ian Taylor, commercial director of Solentim. “This approach means that scientists no longer need to pre-screen for high producing clones (e.g., using fluorescence detection to measure secretion from single cells or colonies). Instead, using the Leap-In Transposase technology, almost every transfected cell is a high producing clone. Combining this with high seeding efficiencies from VIPS has huge practical benefits to the workflow …”
“Establishing and isolating the most suitable cell lines producing [protein pharmaceuticals] is a major manufacturing bottleneck,” added Jeremy Minshull, CEO of ATUM. “We are extremely excited to combine our advanced bioengineering tools with the instrumentation technology of Solentim to accelerate the discovery and development process.”
Source: Solentim
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.